Anal Cancer Market, by Drug Type (Fluorouracil, Cisplatin, Carboplatin, and Others (Others include Mitomycin, Oxaliplatin, Docetaxel, Leucovorin, etc.)), by Cancer Type (Carcinoma In-situ, Squamous Cell Carcinoma, Melanoma, Adenocarcinoma, and Basal Cell

Anal Cancer Market, by Drug Type (Fluorouracil, Cisplatin, Carboplatin, and Others (Others include Mitomycin, Oxaliplatin, Docetaxel, Leucovorin, etc.)), by Cancer Type (Carcinoma In-situ, Squamous Cell Carcinoma, Melanoma, Adenocarcinoma, and Basal Cell Carcinoma), by Treatment Type (Chemotherapy, Surgery, Radiation Therapy, and Immunotherapy), by Distribution Channel (Hospitals & Clinics, Research & Academic Institutes, Long-term Care Centers, and Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Anal cancer is a rare type of cancer in the anal canal. The anal canal is a short tube, about 1-1½ inches long between anal opening and rectum through which stool passes out of the human body. Some of the symptoms associated with anal cancer include anal or rectum bleeding, lump near anus, pain around the anus, itching in the anus, discharge from the anus, changes in bowel habits, and others. Anal cancer can be caused due to a number of risk factors such as human papillomavirus (HPV) infection, having multiple sexual partners, indulging in receptive anal intercourse (anal sex), excessive smoking, medical history of vaginal, cervical or vulvar cancers. Moreover, immune-compromised patients who have a disease or condition which causes weakening of immune system such as organ transplant, human immunodeficiency virus (HIV), and others.
Market Dynamics
The increasing incidence of anal cancer and sexually transmitted diseases, rising research and development activities for the development of novel therapeutics for the treatment of anal cancer, and increasing adoption of inorganic growth strategies such as acquisitions and collaborations by key players operating in the market, are the major factors that are expected to drive growth of the global anal cancer market over the forecast period.
For instance, according to data provided by the Cancer Research U.K. in 2018, around 1,500 new cases of anal cancer are reported every year in the U.K, i.e. four new anal cancer cases daily. The same source also states that the incidence rate of anal cancer in the U.K. is highest in elderly people of age 90 and above.
Key features of the study:
This report provides in-depth analysis of the global anal cancer market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global anal cancer market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Advaxis, Inc., ORYX GmbH and Co. KG, Eli Lilly and Company, Merck KGaA, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Onconova Therapeutics, BioMimetix JV, LLC, Bayer AG, Spectrum Pharmaceuticals Inc., Global BioPharma Inc., Amgen Inc., Atara Biotherapeutics Inc., ISA Pharmaceuticals, Takeda Pharmaceutical Company Limited, Ono Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, Novartis AG, Pfizer Inc., Sanofi, and Johnson & Johnson Private Limited
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global anal cancer market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global anal cancer market
Detailed Segmentation:
Global Anal Cancer Market, By Drug Type:
Fluorouracil
Cisplatin
Carboplatin
Others (Others include Mitomycin, Oxaliplatin, Docetaxel, Leucovorin, etc.)
Global Anal Cancer Market, By Cancer Type:
Carcinoma In-situ
Squamous Cell Carcinoma
Melanoma
Adenocarcinoma
Basal Cell Carcinoma
Global Anal Cancer Market, By Treatment Type:
Chemotherapy
Surgery
Radiation Therapy
Immunotherapy
Global Anal Cancer Market, By Distribution Channel:
Hospitals & Clinics
Research & Academic Institutes
Long-term Care Centers
Pharmacies
Global Anal Cancer Market, By Region:
North America
By Drug Type
Fluorouracil
Cisplatin
Carboplatin
Others (Others include Mitomycin, Oxaliplatin, Docetaxel, Leucovorin, etc.)
By Cancer Type
Carcinoma In-situ
Squamous Cell Carcinoma
Melanoma
Adenocarcinoma
Basal Cell Carcinoma
By Treatment Type
Chemotherapy
Surgery
Radiation Therapy
Immunotherapy
By Distribution Channel
Hospitals & Clinics
Research & Academic Institutes
Long-term Care Centers
Pharmacies
By Country
U.S.
Canada
Latin America
By Drug Type
Fluorouracil
Cisplatin
Carboplatin
Others (Others include Mitomycin, Oxaliplatin, Docetaxel, Leucovorin, etc.)
By Cancer Type
Carcinoma In-situ
Squamous Cell Carcinoma
Melanoma
Adenocarcinoma
Basal Cell Carcinoma
By Treatment Type
Chemotherapy
Surgery
Radiation Therapy
Immunotherapy
By Distribution Channel
Hospitals & Clinics
Research & Academic Institutes
Long-term Care Centers
Pharmacies
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Drug Type
Fluorouracil
Cisplatin
Carboplatin
Others (Others include Mitomycin, Oxaliplatin, Docetaxel, Leucovorin, etc.)
By Cancer Type
Carcinoma In-situ
Squamous Cell Carcinoma
Melanoma
Adenocarcinoma
Basal Cell Carcinoma
By Treatment Type
Chemotherapy
Surgery
Radiation Therapy
Immunotherapy
By Distribution Channel
Hospitals & Clinics
Research & Academic Institutes
Long-term Care Centers
Pharmacies
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Drug Type
Fluorouracil
Cisplatin
Carboplatin
Others (Others include Mitomycin, Oxaliplatin, Docetaxel, Leucovorin, etc.)
By Cancer Type
Carcinoma In-situ
Squamous Cell Carcinoma
Melanoma
Adenocarcinoma
Basal Cell Carcinoma
By Treatment Type
Chemotherapy
Surgery
Radiation Therapy
Immunotherapy
By Distribution Channel
Hospitals & Clinics
Research & Academic Institutes
Long-term Care Centers
Pharmacies
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Drug Type
Fluorouracil
Cisplatin
Carboplatin
Others (Others include Mitomycin, Oxaliplatin, Docetaxel, Leucovorin, etc.)
By Cancer Type
Carcinoma In-situ
Squamous Cell Carcinoma
Melanoma
Adenocarcinoma
Basal Cell Carcinoma
By Treatment Type
Chemotherapy
Surgery
Radiation Therapy
Immunotherapy
By Distribution Channel
Hospitals & Clinics
Research & Academic Institutes
Long-term Care Centers
Pharmacies
By Country
GCC
Israel
Rest of Middle East
Africa
By Drug Type
Fluorouracil
Cisplatin
Carboplatin
Others (Others include Mitomycin, Oxaliplatin, Docetaxel, Leucovorin, etc.)
By Cancer Type
Carcinoma In-situ
Squamous Cell Carcinoma
Melanoma
Adenocarcinoma
Basal Cell Carcinoma
By Treatment Type
Chemotherapy
Surgery
Radiation Therapy
Immunotherapy
By Distribution Channel
Hospitals & Clinics
Research & Academic Institutes
Long-term Care Centers
Pharmacies
By Country/Region
South Africa
Central Africa
North Africa
Company Profiles
Advaxis, Inc.*
Company Overview
Material Portfolio
Financial Performance
Key Highlights
Market Strategies
ORYX GmbH and Co. KG
Eli Lilly and Company
Merck KGaA
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline plc
Onconova Therapeutics
BioMimetix JV, LLC
Bayer AG
Spectrum Pharmaceuticals Inc.
Global BioPharma Inc.
Amgen Inc.
Atara Biotherapeutics Inc.
ISA Pharmaceuticals
Takeda Pharmaceutical Company Limited
Ono Pharmaceutical Co., Ltd.
Sun Pharmaceutical Industries Ltd.
Bristol-Myers Squibb Company
Novartis AG
Pfizer Inc.
Sanofi
Johnson & Johnson Private Limited
“*” marked represents similar segmentation in other categories in the respective section.